PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Submission of Matters to a Vote of Security Holders

PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.


About PUMA BIOTECHNOLOGY, INC. (NASDAQ:PBYI)

Story continues below

Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4.

An ad to help with our costs